Home > Cardiology > ACC 2022 > Prevention > PACIFIC-AF: Low bleeding rates for asundexian in atrial fibrillation

PACIFIC-AF: Low bleeding rates for asundexian in atrial fibrillation

Presented By
Prof. Manesh Patel, Duke University School of Medicine, USA
Conference
ACC 2022
Trial
Phase 2, PACIFIC-AF
The oral factor XIa inhibitor asundexian showed a favourable safety profile in a phase 2 study that investigated 755 patients with atrial fibrillation (AF). In addition, lower bleeding rates were reported for patients who were randomised to asundexian than for those who received apixaban. Thus, factor XI is a promising target to prevent thrombosis in patients with AF, while minimising the risk of bleeding. Factor XI inhibition is hypothesised to reduce the risk of the development of pathological thrombi. In addition, since thrombin can still be formed with factor XI inhibition, it is expected that beneficial blood clots can be formed to prevent bleeding. In contrast, factor Xa inhibitors reduce the risk for pathological thrombi but also hamper thrombin production. The phase 2 PACIFIC-AF trial (NCT04218266) is part of the larger phase 2 PACIFIC programme, which ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on